Navigation Links
Rosemary chicken protects your brain from free radicals
Date:10/30/2007

Rosemary not only tastes good in culinary dishes such as Rosemary chicken and lamb, but scientists have now found it is also good for your brain. A collaborative group from the Burnham Institute for Medical Research (Burnham Institute) in La Jolla, CA and in Japan, report that the herb rosemary contains an ingredient that fights off free radical damage in the brain. The active ingredient in rosemary, known as carnosic acid (CA), can protect the brain from stroke and neurodegeneration that is due to injurious chemical free radicals. These radicals are thought to contribute not only to stroke and neurodegenerative conditions such as Alzheimers, but also to the ill effects of normal aging on the brain.

In two expedited publications by The Journal of Neurochemistry and Nature Reviews Neuroscience, the scientists report for the first time that CA activates a novel signaling pathway that protects brain cells from the ravages of free radicals. In animal models, the scientific group, led by Drs. Takumi Satoh (Iwate University, Japan) and Stuart Lipton (Burnham Institute), found that CA becomes activated by the free radical damage itself, remaining innocuous unless needed, exactly what is wanted in a drug. The scientists call this type of action a pathological-activated therapeutic or PAT drug. A pat represents a gentle tap and not the heavy sledge hammer that some drugs produce, including significant side effects in areas of the body where their effects are not needed and not wanted.

This new type of drug works through a mechanism known as redox chemistry in which electrons are transferred from one molecule to another in order to activate the bodys own defense system, said Stuart A. Lipton, MD, PhD, the senior author on the paper and Director, Professor, and Senior Vice President at the Burnhams Del E. Webb Neuroscience, Aging, and Stem Cell Research Center. Moreover, unlike most new drugs, this type of compound may well be safe and clinically tolerated because it is present in a naturally-occurring herb that is known to get into the brain and has been consumed by people for over a thousand years. Dr. Lipton is also a practicing neurologist at the University of California, San Diego, and therefore knows first-hand that such drugs are critically needed for care of the aging and neurologically-ill patients.

Rosemary is a shrubby evergreen bush and, according to folklore, takes its name from the Virgin Mary, who draped her cloak on the bush, placing a white flower on top of the cloak. By the following morning, the flower had turned blue, and thereafter the plant was known as the Rose of Mary. Rosemary, grown in the Alps since the Middle Ages, has became part of European folk medicine, and was thought to help the nervous system and ward off sickness. Until now, however, the exact chemical pathways involved in its beneficial effects have remained unknown. Additionally, the new scientific work, identifying the compound in rosemary that is beneficial, should allow even better and more effective drugs in this class to be developed in the near future. Along these lines, Satoh and Lipton have filed a United States patent application for a whole series of novel compounds that show increased benefits over rosemary itself. This is not to say that Rosemary chicken is not good for you, said Dr. Satoh, but it means that we can do even better in protecting the brain from terrible disorders such as Alzheimers and Lou Gehrigs disease, perhaps even slowing down the effects of normal aging, by developing new and improved cousins to the active ingredient in rosemary. The authors hope that such drugs can be developed for people over the next few years.


'/>"/>

Contact: Andrea Moser
amoser@burnham.org
858-646-3146
Burnham Institute
Source:Eurekalert

Related biology news :

1. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
2. What comes first…the chicken, the egg, or the bad attitude?
3. Hospitalizations because of chicken pox down dramatically since implementation of vaccine
4. Geoscientists follow arsenic from chicken feed to streambeds
5. UF scientists restore sight to chickens with blinding disease
6. Origen publishes in Nature a robust and versatile method for creating transgenic chickens
7. Arsenic in chicken feed may pose health risks to humans, C&EN reports
8. Bound for destruction: Ubiquitination protects against improper Notch signaling
9. Experiments provide proof of how traveling in groups protects insects
10. Experiments provide proof of how traveling in groups protects insects
11. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
Breaking Biology Technology: